BRL-301

BRL-301 is a universal, allogeneic chimeric antigen receptor T cell (UCAR-T) therapy targeting CD19. It is developed using the TyUCell platform by BRL Medicine and Bangyao Biotechnology. The product consists of gene-modified T cells derived from healthy donors, engineered to express a CAR that targets the B-cell antigen CD19. This approach enables off-the-shelf availability, high accessibility, and reduced manufacturing costs compared to autologous CAR-T therapies. BRL-301 is being investigated for hematological malignancies such as acute lymphoblastic leukemia (ALL), as well as for refractory autoimmune diseases including systemic lupus erythematosus (SLE) and other relapsed or refractory autoimmune conditions. Early clinical studies have demonstrated significant efficacy and safety in both oncology and autoimmune indications[1][3][4][5][6][7].

Other names

Anti CD19 universal chimeric antigen receptor T cell therapyCD19UCARTCD-19UCARTCD 19UCARTUniversal CD19 CAR-T